Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.

DexCom (DXCM) Rises 7% in One Week: What's Driving It?

Amazon

Alphabet

NVIDIA

Alexandria Real Estate Equities

Axon Enterprise

Delta Air Lines

ServiceNow

Palo Alto Networks

S&P Global

T-Mobile US

Visa

Vici Properties

Barron's looked for the most popular stocks in the S&P 500 based on analyst ratings that also have rising 2024 earnings estimates.

Amazon, Alphabet, Nvidia and 12 More Stocks Wall Street Loves for 2024

DexCom is a leading healthcare stock that has seen significant growth, with shares returning close to 1,400% in the past decade. DXCM stock has faced resistance and is currently 37% below its all-time high, partly due to competition from weight loss pills. DexCom's business model focuses on continuous glucose monitoring systems for individuals with diabetes, and it has a rapidly expanding addressable market.

Why DexCom May Be Up To 40% Undervalued

PARIS--(BUSINESS WIRE)--Dexcom has announced the availability of its Dexcom ONE real-time CGM sensor via reimbursement in France.

Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France

Intuitive Surgical

We believe DexCom stock (NASDAQ: DXCM) is a better healthcare pick than Intuitive Surgical stock (NASDAQ: ISRG).

With 2x Potential Returns Is DexCom A Better Pick Over Intuitive Surgical?

DexCom is a major player in the continuous glucose monitoring space, with steadily growing revenues and a breakout year in 2020. DXCM's market cap valuation has reached $40 billion, leading to high expectations for future growth. Dexcom faces new competition from GLP-1 agonist drugs, which could potentially eliminate a significant portion of its target market in the Type 2 Diabetes (T2D) space.

Dexcom Denies Weight Loss Drug Threat To CGM Sales - I'd Be A Little Concerned

DexCom (DXCM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in DexCom (DXCM): Can Its 6.5% Jump Turn into More Strength?

Dexcom stock surged Wednesday after the company allayed concerns that popular weight-loss drugs would tamp on its diabetes devices.

Dexcom Says It Won't Be The Biggest Loser In The Weight-Loss Battle — And Shares Soar

DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.

DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany

DexCom stock (NASDAQ: DXCM) has seen a 17% fall in a month, compared to a 2% fall for the broader S&P500 index.

What's Next For DexCom Stock After A 17% Fall In A Month?

Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock DexCom, Inc. (DXCM) a Buy Now?

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023 at 3:45pm (EDT). Sean Christensen, Vice President, Finance and Investor Relations, will present on behalf of the company at the Baird 2023 G.

Dexcom Announces Upcoming Conference Presentations

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--Dexcom Appoints Rimma Driscoll to Board of Directors.

Dexcom Appoints Rimma Driscoll to Board of Directors

Over the past two and a half years, Nvidia, Intuitive Surgical, Alphabet, Amazon, Dexcom, Shopify, and Palo Alto Networks have split their stocks. In theory, stock splits don't affect a company's market value, but in practice, all eight of these stocks surged after splitting.

1 Stock-Split Stock Billionaires Are Buying Hand Over Fist and 1 Unexpected Stock-Split Stock They're Selling

British American Tobacco

Anheuser-Busch InBev

Coca-Cola

McDonald's

Netflix

Pfizer

The latest jobs report showed a slowing pace of hiring which will affect stock market opportunities. The July jobs report showed slowing hiring with low unemployment.

7 Top Stock Opportunities on the Heels of the Latest Jobs Report

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to Work® in Canada for 2023-24. Awarded by Great Place to Work Institute®, the global authority on workplace culture, this certification is based on direct feedback from employees about their workplace experience, and the sentiment of pride they feel in represe.

Dexcom Canada Achieves Great Place to Work® Certification for Second Consecutive Year

Shockwave Medical

Wegovy and Mounjaro obesity and diabetes drugs are expected to have a significant impact on society and may lead to a decrease in demand for certain medical devices and surgeries. Medical device stocks, such as Shockwave, DexCom, and Intuitive Surgical, have experienced sell-offs due to concerns about the future impact of these drugs. However, there are still millions of overweight and obese individuals who will require medical interventions, creating potential opportunities for these stocks.

The Sell-Off Caused By Wegovy And Mounjaro In Medtech Stocks Offers A Huge Opportunity

Taiwan Semiconductor Manufacturing

Wells Fargo

Uncertainty from geopolitical tensions within the Ukraine war and China issues has led to slower United States labor market growth. In this environment of uncertainty, the United States labor market has displayed a degree of resilience but at a notably slower pace of growth.

What Are the Best Companies to Invest in Now? Our 3 Picks for August

BJ's Restaurants

Coty

D.R. Horton

Livent Corp

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Coty (COTY), BJ's Restaurants (BJRI), DexCom (DXCM), Livent (LTHM) and D.R.

5 Top Stocks Likely to Beat Earnings Estimates

Glucose-monitor maker DexCom Inc. NASDAQ: DXCM was among the top three gainers within the healthcare sector on July 28, advancing 2.33% in the season after gapping higher at the open.

Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher

DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong

Paycom Software

Apple

Arch Capital

Best Buy

Broadridge Financial

Salesforce

Cintas Corp

Etsy

Keysight

Lowe's

Monolithic Power Systems

Microsoft

Motorola Solutions

Norwegian Cruise Line

Nasdaq

NetApp

Insulet

Synopsys

Sysco

Take-Two Interactive Software

Subscribers to  Chart of the Week  received this commentary on Sunday, July 23.

25 S&P 500 Stocks to Target Next Month

Dexcom, Inc. (NASDAQ:DXCM ) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Sean Christensen - Director, Corporate Affairs & Head of IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & CAO Jake Leach - EVP, Chief Operating Officer Conference Call Participants Danielle Antalffy - UBS Robert Marcus - JPMorgan Chase & Co. Jeffrey Johnson - Robert W. Baird & Co. Lawrence Biegelsen - Wells Fargo Securities Joanne Wuensch - Citigroup Matthew Miksic - Barclays Bank Travis Steed - Bank of America Merrill Lynch Matthew Taylor - Jefferies Margaret Kaczor - William Blair & Company Matthew O'Brien - Piper Sandler & Co. Mathew Blackman - Stifel, Nicolaus & Company Marie Thibault - BTIG Jayson Bedford - Raymond James & Associates Steven Lichtman - Oppenheimer Josh Jennings - TD Cowen Michael Polark - Wolfe research Operator Ladies and gentlemen, welcome to the Dexcom Second Quarter 2023 Earnings Release Conference Call.

Dexcom, Inc. (DXCM) Q2 2023 Earnings Call Transcript

DexCom (DXCM) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.17 per share a year ago.

DexCom (DXCM) Beats Q2 Earnings and Revenue Estimates

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News for DexCom Stock (DXCM)